FOXO4-DRI Peptide: Dosage, Protocol, Senolytic Effects, and Anti-Aging Guide

FOXO4-DRI Peptide

FOXO4-DRI is a senolytic peptide designed to selectively remove senescent (aging or damaged) cells. By clearing these dysfunctional cells, it may reduce inflammation, improve tissue function, and support longevity pathways.

What Makes FOXO4 Different

Senescent Cells ↑ → Inflammation ↑ → Aging ↑

FOXO4-DRI → Senescent Cell Clearance → Tissue Function ↑ → Aging Signals ↓

Unlike most peptides that stimulate growth or hormones, FOXO4-DRI works by eliminating damaged cells that accumulate over time. These senescent cells contribute to chronic inflammation and reduced cellular performance.

Reconstitution & Dosing (10 mg Vial)

Precision Dosing → Senescent Targeting → Controlled Clearance → Recovery Phase

Vial Strength 10 mg FOXO4-DRI

Water Added 3.0 mL bacteriostatic water

Concentration 3.33 mg/mL

Conversion 1 unit ≈ 33.3 mcg

Reconstitution Steps

• Draw 3.0 mL bacteriostatic water using a sterile syringe
• Inject slowly down the vial wall to prevent foaming
• Gently swirl or roll the vial (do not shake)
• Ensure solution is fully dissolved and clear
• Refrigerate immediately after mixing (2–8°C)
• Protect from light and label with reconstitution date

Tip: For doses under 10 units, consider a 30–50 unit insulin syringe for improved accuracy.

Standard Protocol (Gradual Approach)

Weeks 1–4

Dose 250 mcg

Units ~7.5 units (0.075 mL)

Low Dose

Weeks 5–8

Dose 375 mcg

Units ~11 units (0.11 mL)

Moderate Dose

Weeks 9–12

Dose 500 mcg

Units ~15 units (0.15 mL)

Full Dose

Weeks 13–16

Dose 500 mcg

Units ~15 units (0.15 mL)

Maintenance

Frequency: Once daily subcutaneous injection
Typical Range: 250–500 mcg daily

FOXO4-DRI Protocol (Senolytic Cycle)

Days 1–3 (Initial Cycle)

Dose 5 mg

Frequency Once daily

Senolytic Start

Optional Extension

Dose 5–10 mg

Duration 3–5 days total

Short Cycle

Repeat Cycle

Frequency Every 4–8 weeks

Goal Cellular cleanup & recovery

Recovery Phase

Protocol Type: Short-cycle senolytic (not continuous use)
Administration: Subcutaneous injection

Why FOXO4 Is Cycled

• Used in short “clearing” phases
• Not designed for continuous dosing
• Recovery allows tissue repair
• Matches current senolytic research approach

How FOXO4 Works

FOXO4 Disruption → p53 Activation → Senescent Cell Apoptosis → Cellular Cleanup

FOXO4-DRI disrupts the FOXO4–p53 interaction in senescent cells, forcing them into apoptosis. This removes dysfunctional cells and allows healthier cells to function more efficiently.

What Are Senescent Cells?

• Cells that no longer divide but remain active
• Release inflammatory signals (SASP)
• Accumulate with age and damage
• Drive chronic inflammation and aging

Expected Effects

• Temporary fatigue during cycle (common)
• Reduction in inflammation over time
• Improved recovery and tissue function
• Potential longevity benefits (research ongoing)

Potential Side Effects

• Fatigue or flu-like symptoms
• Mild injection site irritation
• Temporary detox-like response
• Limited long-term human data

Best Practices

• Use only in short cycles (3–5 days)
• Allow 4–8 weeks between cycles
• Stay hydrated
• Avoid stacking initially
• Track response and recovery

Stacking Considerations

• Often paired with NAD+ or mitochondrial support
• Best used AFTER senolytic cycle
• Avoid aggressive stacks initially

Storage

Lyophilized: Store at −20°C (−4°F)
Reconstituted: Refrigerate at 2–8°C (36–46°F)
Use within 30 days

Important Notes

• Investigational peptide (not FDA-approved)
• Human data is limited
• Protocols are research-based
• Use intermittently, not continuously

Important Disclaimer

FOXO4-DRI is an investigational compound. This content is for educational purposes only and does not constitute medical advice.

Peptide Directory →